No Prescription |
 |
 | ||
|
Aerius Generic Desloratadine |
|
| ||
No Prescription » Prescription Drugs 1 » Aerius Generic Desloratadine Aerius is an antihistamine used to treat the symptoms of hay fever and other allergic conditions such as watery eyes runny nose itching eyes and sneezing. It may also be used to treat hives. Buy Aerius Generic Desloratadine and other Prescription Drugs 1 products online at Medstore. 3629
About Aerius Generic Desloratadine: Product Type: Prescription Drugs 1 Aerius ( Generic Desloratadine ) Aerius (Generic Desloratadine) Generic Desloratadine 5mg 20 Tablets Generic Desloratadine Aerius
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
